Skip to main content
SpringerLink
Log in

Genetic variations in cytochrome P450 (CYP) 2D6 activity may have important clinical consequences for some drugs

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 2009; 48(11): 689–23

    Article  PubMed  CAS  Google Scholar 

  2. Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009; 48(12): 761–804

    Article  PubMed  CAS  Google Scholar 

  3. Zhou SF, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008; 9(8): 738–84

    Article  PubMed  CAS  Google Scholar 

  4. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369(1): 23–37

    Article  PubMed  CAS  Google Scholar 

  5. Cascorbi I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur J Clin Invest 2003 Nov; 33Suppl. 2: 17–22

    Article  PubMed  CAS  Google Scholar 

  6. Wennerholm A, Dandara C, Sayi J, et al. The African-specific CYP2D6* 17 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002; 71(1): 77–88

    Article  PubMed  CAS  Google Scholar 

  7. Sunwoo YE, Ryu J, Jung H, et al. Disposition of chlorpromazine in Korean healthy subjects with CYP2D6 wild-type and *10B mutation [abstract]. Clin Pharmacol Ther 2004; 73: PII–146

    Google Scholar 

  8. Roh HK, Chung JY, Oh DY, et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 2001; 52(3): 265–71

    Article  PubMed  CAS  Google Scholar 

  9. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with anti-depressants. A pilot study. Clin Pharmacol Ther 2004; 75: 386–93

    Article  PubMed  CAS  Google Scholar 

  10. De Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66(1): 15–27

    Article  PubMed  Google Scholar 

  11. Tateishi T, Watanabe M, Kumai T, et al. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci 2000; 67(24): 2913–20

    Article  PubMed  CAS  Google Scholar 

  12. Bijl MJ, Visser LE, Hofman A, et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of anti-depressants. Br J Clin Pharmacol 2008 Apr; 65(4): 558–64

    Article  PubMed  CAS  Google Scholar 

  13. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41(7): 453–70

    Article  PubMed  CAS  Google Scholar 

  14. Otani K, Aoshima T. Pharmacogenetics of classical and new anti-psychotic drugs. Ther Drug Monit 2000; 22(1): 118–21

    Article  PubMed  CAS  Google Scholar 

  15. Patsopoulos NA, Ntzani EE, Zintzaras E, et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 2005; 15: 151–8

    Article  PubMed  CAS  Google Scholar 

  16. Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 2007; 81(6): 899–902

    Article  PubMed  CAS  Google Scholar 

  17. Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009; 85(1): 31–5

    Article  PubMed  CAS  Google Scholar 

  18. Shiran MR, Chowdry J, Rostami-Hodjegan A, et al. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 2003; 56(2): 220–4

    Article  PubMed  CAS  Google Scholar 

  19. Wu D, Otton SV, Sproule BA, et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993; 35(1): 30–4

    Article  PubMed  CAS  Google Scholar 

  20. Lotsch J, Skarke C, Liefhold J, et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004; 43(14): 983–1013

    Article  PubMed  Google Scholar 

  21. Kirchheiner J. CYP2D6 phenotype prediction from genotype: which system is the best? Clin Pharmacol Ther 2008; 83(2): 225–7

    Article  PubMed  CAS  Google Scholar 

  22. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008; 83(1): 160–6

    Article  PubMed  CAS  Google Scholar 

  23. Takimoto CH. Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments? Nat Clin Pract Oncol 2007; 4(3): 152–3

    Article  PubMed  Google Scholar 

  24. Lee JT, Kroemer HK, Silberstein DJ, et al. The role of genetically determined polymorphic drug metabolism in the β-blockade produced by propafenone. N Engl J Med 1990; 322(25): 1764–8

    Article  PubMed  CAS  Google Scholar 

  25. Fux R, Morike K, Prohmer AM, et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 2005; 78(4): 378–87

    Article  PubMed  CAS  Google Scholar 

  26. Bijl MJ, Visser LE, van Schaik RH, et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in β-blocker users. Clin Pharmacol Ther 2009 (1); 85: 45–50

    Article  PubMed  CAS  Google Scholar 

  27. Yasuda SU, Zannikos P, Young AE, et al. The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol 2002; 53(5): 519–25

    Article  PubMed  CAS  Google Scholar 

  28. Lessard E, Yessine MA, Hamelin BA, et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 2001; 21(2): 175–84

    Article  PubMed  CAS  Google Scholar 

  29. Yin OQ, Shi XJ, Tomlinson B, et al. Effect of CYP2D6*10 allele on the pharmacokinetics of loratadine in Chinese subjects. Drug Metab Dispos 2005; 33(9): 1283–7

    Article  PubMed  CAS  Google Scholar 

  30. Pilotto A, Franceschi M, D’Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 2009; 73(10): 761–7

    Article  PubMed  CAS  Google Scholar 

  31. Brynne N, Dalen P, Alvan G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 1998; 63(5): 529–39

    Article  PubMed  CAS  Google Scholar 

  32. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41(2): 89–295

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Genetic variations in cytochrome P450 (CYP) 2D6 activity may have important clinical consequences for some drugs. Drugs Ther. Perspect 26, 21–26 (2010). https://doi.org/10.2165/11205190-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11205190-000000000-00000

Search

Navigation